BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » FUJIFILM Expands Its Reign in Regenerative Medicine
FUJIFILM Expands Its Reign in Regenerative Medicine

FUJIFILM Expands Its Reign in Regenerative Medicine

September 8, 2016 By Cade Hildreth (CEO) Leave a Comment

It has been a major week in the stem cell industry, with partnerships, licensing deals, and pre-clinical findings recently announced. Check out the latest coverage below.

Discover class-defining bioproduction tools.

Cynata Shares Jump as Japan’s FUJIFILM Negotiates Deal to Commercialize Cymerus™ Stem Cell Technology

Cynata Therapeutics Limited (ASX: CYP), announced the execution of a term sheet with FUJIFILM Corporation of Japan for the development and commercialisation of certain Cynata technology, including Cynata’s lead stem cell product, CYP-001. According to the term sheet, Cynata would grant FUJIFILM an option to an “exclusive, worldwide licence to market and sell Cynata’s lead MSC product for prevention and treatment of graft-versus-host disease (GvHD), as well as (a) an option to negotiate a licence for manufacturing those products, and (b) certain rights to Cynata’s proprietary Cymerus™ technology for the prevention and treatment of other diseases.”

Infographic Highlights Preclinical Applications of iPSC-Derived Cells

Founded in 2001 and headquartered in Cologne, Germany, Axiogensis is one of a small number of companies specializing in induced pluripotent stem cell (iPSC) products. In the first infographic, Axiogenesis presents the preclinical applications possible with induced pluripotent stem cells (iPSCs). The second infographic features cell types that can be derived from human iPSCs, including cell types offered by Axiogenesis.

European Society of Cardiology (ESC) Congress Presentation Reveals Results From Pre-Clinical Study Using CardioCell’s Stem Cells for Acute Myocardial Infarction

CardioCell LLC, a company using allogeneic stem cells for cardiovascular indications, announces data from its pre-clinical study “Mesenchymal stem cells grown under chronic hypoxia traffic to regions of myocardial infarction, suppress splenic natural killer cells, and attenuate adverse remodeling in mice with large acute MI.” Pre-clinical results using a murine model show that intravenous injection of CardioCell’s ischemia-tolerant mesenchymal stem cells (itMSCs) improve cardiac function following an acute myocardial infarction (AMI).

Rooster DevServices

BrainXell Enters into Global Licensing Agreement for Induced Pluripotent Stem Cell (iPSC) Patent Technology with iPS Academia Japan, Inc.

BrainXell Inc. (Madison, Wisconsin) and iPS Academia Japan, Inc. (Kyoto, Japan) have announced a global licensing agreement covering some of iPS Academia Japan’s induced pluripotent stem (iPS) cell patent portfolio. BrainXell may now develop and commercialize iPS-derived cells and offer related services to its customers under this non-exclusive agreement. BrainXell uses its proprietary technology to direct human iPSCs to subtype-specific neural progenitors followed by expansion and rapid maturation.

Cord Blood Banking Industry – Key Benchmarks to Track (and Why You Should Care)

Benchmarks are critical to assess, because the cord blood banking industry has matured substantially over the past few years, creating both serious threats and novel opportunities. Therefore, judging individual company performance relative to the broader cord blood marketplace has become substantially more complex. Marketing pressures are also impacting the industry, with the term “cord blood” becoming one of the 20 most expensive search terms on Google.

bitbio

Top 10 Cord Blood Banks Worldwide

This post considers the top 10 most influential and innovative cord blood banks worldwide. It is critical to be educated about these companies, because they set important standards and practices that affect all market participants. The criteria used for this analysis was the degree to which a cord blood bank has unique attributes that set it apart from the rest of the marketplace, such as having a large global reach, innovative business model, unique products or services, advanced marketing models, or other world-class attributes which distinguish it from the competition.

Event Update

The FDA’s public workshop entitled “Scientific Evidence in the Development of Human Cells, Tissues, and Cellular and Tissue-Based Products Subject to Premarket Approval” is tomorrow, September 8, 2016. Let me know if you’ll be there?

Pluristyx
Rate this post

Filed Under: iPS Cells, MSCs Tagged With: Axiogenesis, BrainXell, CardioCell, cynata, FUJIFILM

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

iPSC derived cell therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

Stem cell companies

List of Stem Cell Companies Worldwide (2022)

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.